SCHEDULE 13G/A: Sabby Entities Disclose 4.9% Passive Stake in InMed Pharmaceuticals

Sabby Management, Sabby Volatility Warrant Master Fund, and Hal Mintz have jointly reported a passive beneficial ownership of 4.9% in InMed Pharmaceuticals Inc.'s common stock as of December 31, 2024.

Summary

• Sabby Management, LLC, Sabby Volatility Warrant Master Fund Ltd, and Hal Mintz have filed an Amendment No. 1 to Schedule 13G, reporting their beneficial ownership in InMed Pharmaceuticals Inc.
• As of December 31, 2024, the reporting persons collectively beneficially own 36,135 shares of InMed Pharmaceuticals Inc. Common Stock.
• This represents 4.9% of the outstanding class of InMed Pharmaceuticals Inc. Common Stock.
• The reporting persons share both voting and dispositive power over all 36,135 shares.
• The filing indicates that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: Neutral. This is a routine disclosure of beneficial ownership, providing factual information without indicating positive or negative performance or strategic shifts.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of beneficial ownership and does not provide information related to broader industry trends or competitors for InMed Pharmaceuticals Inc. It only indicates an investment by Sabby entities.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant passive ownership stakes in the company.

Key Dates

Keywords

InMed Pharmaceuticals, Sabby Management, Sabby Volatility Warrant Master Fund, Hal Mintz, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Passive Investment, Equity Stake